Literature DB >> 21744039

Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades.

E Ahlstrand1, K Svensson, L Persson, U Tidefelt, B Söderquist.   

Abstract

The aim of this study was to determine if there was a long-term increase in glycopeptide minimum inhibitory concentration (MIC) values, MIC creep, among bloodstream isolates of Staphylococcus epidermidis and S. haemolyticus isolated from patients with hematological malignancies. We conducted a retrospective single-center study where all positive blood cultures of S. epidermidis (n = 387) and S. haemolyticus (n = 19) isolated from patients with hematological malignancies during three decades, 1980 to 2009, were re-evaluated for the presence of reduced susceptibility to vancomycin and teicoplanin. Three different methods for the detection of reduced susceptibility to glycopeptides were used; standard Etest, macromethod Etest, and glycopeptide resistance detection (GRD) Etest. The median MIC value for vancomycin was 2 mg/L. MIC values for vancomycin and teicoplanin did not show any statistically significant increase during the study period. The presence of heterogeneously glycopeptide-intermediate staphylococci (hGIS) was analyzed among 405 coagulase-negative staphylococci (CoNS) isolates. hGIS were found in 31-45% of the CoNS isolates by the macromethod Etest and in 53-67% by the GRD Etest during the three decades. In conclusion, we did not observe any long-term glycopeptide MIC creep determined by the standard Etest, although a high and increasing proportion of heterogeneous vancomycin resistance was observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744039     DOI: 10.1007/s10096-011-1228-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Glycopeptide resistance in staphylococci.

Authors:  K Hiramatsu; H Hanaki
Journal:  Curr Opin Infect Dis       Date:  1998-12       Impact factor: 4.915

3.  In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

Authors:  L Herwaldt; L Boyken; M Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

4.  Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy.

Authors:  K Sieradzki; R B Roberts; D Serur; J Hargrave; A Tomasz
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

5.  Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Authors:  F W Goldstein; A Coutrot; A Sieffer; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study.

Authors:  E Tacconelli; M Tumbarello; K G Donati; M Bettio; T Spanu; F Leone; L A Sechi; S Zanetti; G Fadda; R Cauda
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

7.  Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.

Authors:  F Biavasco; C Vignaroli; R Lazzarini; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus.

Authors:  J W Froggatt; J L Johnston; D W Galetto; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 9.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.

Authors:  R N Grüneberg; W Hryniewicz
Journal:  Int J Antimicrob Agents       Date:  1998-11       Impact factor: 5.283

View more
  12 in total

1.  Tuf gene sequence analysis has greater discriminatory power than 16S rRNA sequence analysis in identification of clinical isolates of coagulase-negative staphylococci.

Authors:  Sang Mee Hwang; Myoung Shin Kim; Kyoung Un Park; Junghan Song; Eui-Chong Kim
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

2.  Heterogeneous glycopeptide intermediate Staphylococcus epidermidis isolated from prosthetic joint infections.

Authors:  S Tevell; C Claesson; B Hellmark; B Söderquist; Å Nilsdotter-Augustinsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-14       Impact factor: 3.267

3.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis.

Authors:  Kyung-Hwa Park; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Jayawant N Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.

Authors:  S Albac; D Labrousse; D Hayez; N Anzala; D Bonnot; P Chavanet; E Aslangul; D Croisier
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis.

Authors:  J Domínguez-Herrera; F Docobo-Pérez; R López-Rojas; C Pichardo; R Ruiz-Valderas; J A Lepe; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 6.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Authors:  Catherine J Byrne; Jason A Roberts; Brett McWhinney; Jerome P Fennell; Philomena O'Byrne; Evelyn Deasy; Sean Egan; Ronan Desmond; Helen Enright; Sheila A Ryder; Deirdre M D'Arcy; Johnny McHugh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Reduced Vancomycin Susceptibility, MRSA and Treatment Failure in Pediatric Staphylococcus aureus Bloodstream Infections.

Authors:  Ethan Canty; Benjamin Carnahan; Tara Curley; Emily Anususinha; Rana F Hamdy; Jessica E Ericson
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 2.129

9.  The antimicrobial susceptibility, biofilm formation and genotypic profiles of Staphylococcus haemolyticus from bloodstream infections.

Authors:  Patricia Vollú Silva; Raquel Souza Cruz; Luiz Sérgio Keim; Geraldo Renato de Paula; Bernadete Teixeira Ferreira Carvalho; Leonardo Rocchetto Coelho; Maria Cícera da Silva Carvalho; Joel Mauricio Corrêa da Rosa; Agnes Marie Sá Figueiredo; Lenise Arneiro Teixeira
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

10.  Long-term molecular epidemiology of Staphylococcus epidermidis blood culture isolates from patients with hematological malignancies.

Authors:  Erik Ahlstrand; Bengt Hellmark; Karolina Svensson; Bo Söderquist
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.